Farmaforum Partnering Day 2026

23 Sept 2026 | Madrid, Spain

InvestmentUpdated on 14 September 2026

Patent-Pending Nanotechnological Platform to Redirect Immune Cells Against Cancer

Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM

Madrid, Spain

About

Our product is a proprietary, patent-pending nanotechnology platform designed to improve cancer immunotherapy by selectively connecting immune cells with tumor cells.

The technology promotes immune cell–tumor interaction and redirects the immune response toward cancer cells, without the need for complex genetic modification of immune cells.

It has the potential to provide a simpler, more versatile and cost-effective approach to immune cell-based therapies, while improving their therapeutic performance. The platform is being developed for oncology applications and has the potential to be adapted to different tumor types and immunotherapeutic strategies.

We are seeking investment and strategic partners to accelerate preclinical development, expand validation and advance toward clinical translation and commercialization.

Stage

  • Startup

Applies to

  • Biotech, Pharma and Cosmetics
  • Healthcare
  • Nano- and Microtechnologies

Organisation

Similar opportunities